ReviewPharmaceuticals (Basel, Switzerland)2022
Multicomponent Reactions for the Synthesis of Active Pharmaceutical Ingredients.
Review in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Metabolic engineering ofSynthetic and systems biotechnology · 2027Article
- Multicomponent Selective and Efficient Synthesis of Spiro[furo[2,3-Molecules (Basel, Switzerland) · 2026Article
- Blue Light-Mediated Multicomponent Synthesis of 5-Amino-4-chalcogenyl-1H-pyrazoles.The Journal of organic chemistry · 2026Article
- α-Ketoglutaric acid in Ugi reactions and Ugi/aza-Wittig tandem reactions.Beilstein journal of organic chemistry · 2025Article
- Formaldehyde surrogates in multicomponent reactions.Beilstein journal of organic chemistry · 2025Review
- Accessing Promising Passerini Adducts in Anticancer Drug Design.Molecules (Basel, Switzerland) · 2024Article
- Benzenesulfonamide decorated dihydropyrimidin(thi)ones: carbonic anhydrase profiling and antiproliferative activity.RSC medicinal chemistry · 2024Article
- Diastereoselective ZnClMolecules (Basel, Switzerland) · 2024Article
- Multicomponent reactions driving the discovery and optimization of agents targeting central nervous system pathologies.Beilstein journal of organic chemistry · 2024Review
- The Ugi4CR as effective tool to access promising anticancer isatin-based α-acetamide carboxamide oxindole hybrids.Beilstein journal of organic chemistry · 2024Article
- A facile three-component route to powerful 5-aryldeazaalloxazine photocatalysts.Beilstein journal of organic chemistry · 2024Article
- Applying green chemistry principles to iron catalysis: mild and selective domino synthesis of pyrroles from nitroarenes.Chemical science · 2023Article
- Reformulating Reactivity Design for Data-Efficient Machine Learning.ACS catalysis · 2023Article
- Accelerating Drug Discovery: Synthesis of Complex Chemotypes via Multicomponent Reactions.ACS medicinal chemistry letters · 2023Review
- Ugi Four-Component Reactions Using Alternative Reactants.Molecules (Basel, Switzerland) · 2023Review
- 4-(Aryl)-Benzo[4,5]imidazo[1,2-Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Multicomponent reactions 9i.e., those that engage three or more starting materials to form a product that contains significant fragments of all of them), have been widely employed in the construction of compound libraries, especially in the context of diversity-oriented synthesis. While relatively less exploited, their use in target-oriented synthesis offers significant advantages in terms of synthetic efficiency. This review provides a critical summary of the use of multicomponent reactions for the preparation of active pharmaceutical principles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.